Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Transforming Biomarker Development with Exceptional Responders.

Trends in cancer - 1 Jan 2018

Jonsson Philip, Taylor Barry S

Abstract excerpt

Curative therapy for cancer patients with advanced-stage disease remains elusive. While rare outlier responses to anticancer therapies exist, barriers limit our understanding of the molecular and genetic basis of such profound, life-altering responses. Here, we describe how phenotype-to-genotype studies are elucidating the molecular underpinnings of outlier responses and informing strategies to extend such...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Pharmacological
Share to Biomarkers, Tumor
Share to Genetic Association Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Predisposition to Disease

Share to Genomics

Share to Molecular Targeted Therapy

Share to Neoplasms

Share to Precision Medicine

Source

Open in PubMed Open full text

Identifiers

PMID: 29413420
DOI: 10.1016/j.trecan.2017.11.004
PMCID: PMC5806204

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Transforming Biomarker Development with Exceptional Responders.PMID 29413420Read ↗

What have we learned from exceptional tumour responses?: Review and perspectives.Semantic proximity Read ↗

Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment.Semantic proximity Read ↗

Rare Germline Variants in Immune and Drug Target Genes Among Cancer Exceptional RespondersSemantic proximity Read ↗

The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study.Semantic proximity Read ↗

Molecular Profiling of Exceptional Responders to Cancer Therapy.Semantic proximity Read ↗

Genomic Predictors Associated With Exceptional Response to Systemic Therapy in Advanced Pancreatic Cancer.Semantic proximity Read ↗

Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy.Semantic proximity Read ↗

Back to Broad? How Molecular Profiling Facilitates Targeted Therapies of Overlapping Phenotypes.Semantic proximity Read ↗

Functional precision oncology using patient-derived assays: bridging genotype and phenotype.Semantic proximity Read ↗

Dissecting the Contributions of Cooperating Gene Mutations to Cancer Phenotypes and Drug Responses with Patient-Derived iPSCs.Semantic proximity Read ↗

RADical response puts an exceptional responder in CHKmate: a synthetic lethal curative response to DNA-damaging chemotherapy?Semantic proximity Read ↗

Mining the genomes of exceptional responders.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.